Seelos Therapeutics Stock News

Nuveen Asset Management LLC purchased a new stake in Seelos Therapeutics, Inc. (NASDAQ:SEEL) in the second quarter, Holdings Channel.com reports. The fund purchased 162,606 shares of the companys stock, valued at approximately $429,000. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. First []

(RTTNews) - iX Biopharma said that it will license to Seelos Therapeutics Inc (SEEL) its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology. As per the license agreement, iX Biopharma will receive a US$9 million upfront

Seelos Therapeutics (NASDAQ:SEEL) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings & Valuation This table compares Seelos Therapeutics and Kadmons revenue, earnings per share and valuation. []

Seelos Therapeutics, Inc. (NASDAQ:SEEL) has earned a consensus rating of Buy from the six research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued [] The post Seelos Therapeutics, Inc. (NASDAQ:SEEL) Receives Consensus Recommendation of Buy from Brokerages appeared first on ETF Daily News .

Northern Trust Corp increased its stake in Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 520.8% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 760,056 shares of the companys stock after buying an additional 637,626 shares during the period. Northern Trust Corp owned 0.97% of Seelos Therapeutics []

Equities research analysts expect that Seelos Therapeutics, Inc. (NASDAQ:SEEL) will post earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Seelos Therapeutics earnings. Seelos Therapeutics reported earnings of ($0.13) per share in the same quarter last year, which would suggest a positive year over []

Amalgamated Bank bought a new position in Seelos Therapeutics, Inc. (NASDAQ:SEEL) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 14,317 shares of the companys stock, valued at approximately $38,000. Several other large investors have also recently made changes to their positions in SEEL. BlackRock Inc. increased its position in Seelos Therapeutics by []

Seelos Therapeutics, Inc. (SEEL) with the stream of -3.72% also noticed, India Morgan Stanley (MS) encountered a rapid change of -0.54% in the last hour of Wednesdays trading session. Seelos The post Explosive Stock: Seelos Therapeutics, Inc. (NASDAQ:SEEL), Morgan Stanley (NYSE:MS) appeared first on Stocks Equity .

WASHINGTON (dpa-AFX) - Clinical-stage biopharmaceutical company Seelos Therapeutics, Inc. (SEEL), on Wednesday announced the placement of a $22 million senior secured convertible note and shares o

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a

iX Biopharma has inked an exclusive agreement to license its lead drug under development, Wafermine, to Seelos Therapeutics Inc (NASDAQ: SEEL ). Seelos will have exclusive worldwide rights for Wafermine, except China, including Hong Kong, Macau, and Taiwan - for which iX Biopharma will retain the rights. Seelos will also have worldwide rights to products incorporating R- and S- enantiomers of ketamine Full story available on Benzinga.com

Cubist Systematic Strategies LLC raised its stake in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 201.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 160,000 shares of the companys stock after purchasing an additional 107,000 shares during the []